Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
Ascelia Pharma är ett läkemedelsbolag. Bolaget är specialiserat inom utveckling av särläkemedel inom onkologi (cancer). Bolaget utvecklar diverse läkemedelskandidater, där störst användning återfinns inom behandling av cancer som drabbat lever och magsäck. Bolaget grundades år 2000 och har huvudkontor i Malmö, Sverige, men är verksamt på en global marknad.
Ascelia Pharma is expected to release its Q3 2026 interim report on 5 November 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company’s latest developments in a live online event.
Ascelia Pharma yesterday disclosed the findings from its 9 September Type A meeting with the FDA and discussed them at an investor call. The headline is that the FDA maintains its position that additional clinical evidence is required, but no longer presents a new clinical study with new patients as the only way to generate it.
Välkommen med i Inderes community!
Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!
Gratisanvändare
Stock market's most popular morning newsletter
Tillgång till analytikerkommentarer och rekommendationer
Vårt eget aktiescreeningsverktyg
Premiumanvändare
Alla bolagsrapporter och djupanalyser
Premiumverktyg (insidertransaktioner och aktiescreeningsverktyg)
Premiumkolumner: Gästkolumn, expertinsikter
Inderes MCP - Inderes-data direkt till dina AI-verktyg
Ascelia Pharma is expected to release its Q2 2026 results on 20 August 2026. The following day at 10:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event.
* Type A meeting with the FDA scheduled for September 9 * Implementing cost-saving measures * Conf call at 10am CET Recent and upcoming relevant events Following the July 2, 2026 Complete Response Letter for Orviglance, which cited concerns over the ...
Ascelia Pharma announced today that the FDA has scheduled a Type A meeting for 9 September 2026 to discuss the Complete Response Letter issued in early July. The company has submitted a briefing package addressing each of the topics raised by the agency.
